Abstract：Objective: To explore the specific application value of the combined detection of serum miR-424, miR-503 and CA199 in the prognosis assessment of pancreatic cancer. Methods: 80 patients with pancreatic cancer who were admitted to our hospital from March 2022 to March 2024 were selected. The levels of miR-424, miR-503 and CA199 in serum were determined by qRT-PCR. According to the prognosis of the patients, they were divided into the good prognosis group and the poor prognosis group. Logistic regression analysis was used to identify the influencing factors of poor prognosis. The receiver operating characteristic (ROC) curve was used to analyze the predictive value of poor prognosis. Results: The preoperative serum levels of miR-424, miR - 503, and CA199 in the poor prognosis group were significantly higher than those in the good prognosis group(P<0.05). Before the surgery, the levels of serum miR-424, miR-503 and CA199 in the poor prognosis group were significantly higher than those in the good prognosis group (P<0.05). The median survival time of patients with stage III, lymph node metastasis, and low differentiation was significantly shorter than that of patients with stage I-II, no lymph node metastasis, and moderate/high differentiation (P<0.05). The levels of serum miR-424, miR-503 and CA199 before the surgery were all independent risk factors for poor prognosis in pancreatic cancer patients (P<0.05). The AUC of combined detection of serum miR-424, miR-503 and CA199 was significantly higher than that of single indicator detection (P<0.05). Conclusion: The combined detection of serummiR-424, miR-503, andCA199has important clinical significance in the prognosis evaluation of pancreatic cancer. It can provide a basis for individualized treatment and contribute to revealing the molecular mechanism of the occurrence and development of pancreatic cancer. In the future, combining with emerging biomarkers is expected to further expand its application scope.
韩强, 成颖, 赵云虹. 血清miR-424 miR-503联合CA199对胰腺癌患者术后预后的预测价值[J]. 河北医学, 2026, 32(1): 99-104.
HAN Qiang, CHENG Ying, ZHAO Yunhong. The Predictive Value of Combined SerummiR-424 miR-503 and CA199 for Postoperative Prognosis in Pancreatic Cancer Patients. HeBei Med, 2026, 32(1): 99-104.
[1] 闵科,蒋嘉萍,王维民,等.I-125粒子植入改善接受抗PD-1联合化疗的胰腺癌患者的预后[J].复旦学报(医学版),2025,52(1):107-113. [2] 刘光年,田孝东,杨尹默.从技术到策略—2023年胰腺癌治疗热点聚焦[J].中国实用外科杂志,2024,44(1):74-78. [3] Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer[J]. Dis Model Mech,2021,14(4):47662. [4] Shi XH, Li X, Zhang H, et al. A five-microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data[J]. Sci Rep,2021,8(1):7638. [5] Li ZY, Zhu SS, Chen XJ, et al. ARID1A suppresses malignant transformation of human pancreatic cells via mediating senescence-associatedmiR-503/CDKN2A regulatory axis[J]. Biochem Biophys Res Commun,2020,493(2):1018-1025. [6] 曾莲丽,李双双,岳鹏飞,等.一般临床特征与血液学参数在胰腺导管腺癌根治性切除术患者中的预后价值研究[J].四川大学学报(医学版),2024,55(3):708-716. [7] Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter[J]. Biochim Biophys Acta Rev Cancer,2021,1875(2):188409. [8] Dastmalchi N, Baradaran B, Banan Khojasteh SM, et al.miR-424: a novel potential therapeutic target and prognostic factor in malignancies[J].Cell Biol Int,2021,45(4):720-730. [9] Chen J, Wang H, Zhou L, et al. A combination of circulating tumor cells andCA199improves the diagnosis of pancreatic cancer[J].Clin Lab Anal,2022,36(5):24341. [10] 贾明昊,张石垒,刘铁兵,等.p53蛋白表达与胰腺癌淋巴结转移,脉管浸润,神经浸润相关性的系统评价和Meta分析[J].世界华人消化杂志,2024,32(5):376-386.
2026, Vol. 32 
冀公网安备13080202000786号